Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
PROTAC SMARCA2 degrader-25
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "PROTAC SMARCA2 degrader-25" in MCE Product Catalog:
Cat. No.: HY-169276
CAS No.: 2770571-17-8
Target:
Research Areas:
PROTAC SMARCA2 degrader-25 is a PROTAC degrader targeting SMARCA2. PROTAC SMARCA2 degrader-25 is applicable to the research of smarca4-deficient cancers and multiple myeloma .
Cat. No.: HY-162813
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-25 is a selective SMARCA2/SMARCA4 PROTAC degrader with selective anti-tumor activity. PROTAC SMARCA2/4 degrader-25 is activated by endogenous GSH, forms a ternary complex with SMARCA2 or SMARCA4 and VHL E3 ubiquitin ligase, and mediates degradation via the proteasome pathway. PROTAC SMARCA2/4 degrader-25 induces DNA damage and apoptosis, and inhibits cancer cell proliferation. PROTAC SMARCA2/4 degrader-25 is applicable to lung cancer-related research .
Cat. No.: HY-169487
CAS No.: 2755762-94-6
Research Areas:
SMARCA2 ligand-12 is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). SMARCA2 ligand-12 can be used for synthesis PROTAC SMARCA2 degrader-25 (HY-169276) .
Cat. No.: HY-169488
Research Areas:
SMARCA2 ligand-12-3-methylazetidin is a target protein ligand-linker conjugate that incorporates a ligand for SMARCA2 (HY-169487), and a PROTAC linker (HY-W052601), which recruit E3 ligases. SMARCA2 ligand-12-3-methylazetidin can be used to synthesize PROTAC SMARCA2 degrader-25 (HY-169276) .
Cat. No.: HY-162815
Research Areas:
PROTAC SMARCA2/4 degrader-26 is a SMARCA2/4 PROTAC degrader with selective anti-tumor activity against lung cancer cells. PROTAC SMARCA2/4 degrader-26 degrades SMARCA2 and SMARCA4 via the PROTAC-mediated proteasomal pathway. It induces DNA damage and apoptosis in tumor cells, while inhibiting migration and colony formation of lung cancer cells; in addition, it damages normal vascular endothelial cells and exhibits significant off-target-related cytotoxicity. PROTAC SMARCA2/4 degrader-26 serves as the parent scaffold to construct the GSH-responsive prodrug PROTAC SMARCA2/4 degrader-25 (HY-162813), a derivative that shows drastically reduced cytotoxicity against normal cells. PROTAC SMARCA2/4 degrader-26 can be used in lung cancer-related research .
Cat. No.: HY-162814
Research Areas:
SMARCA2/4-ligand-3 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). SMARCA2/4-ligand-3 can be used for synthesis PROTAC SMARCA2/4-degrader-25 (HY-162813) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
